- Trials with a EudraCT protocol (75)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
75 result(s) found for: Very Low Density Lipoprotein.
Displaying page 1 of 4.
EudraCT Number: 2004-003807-19 | Sponsor Protocol Number: 0653A-071 | Start Date*: 2004-12-21 | |||||||||||
Sponsor Name:Merck & Co., Inc. | |||||||||||||
Full Title: A Study to Evaluate the Efficacy and Safety of Ezetimibe/Simvastatin and Fenofibrate Coadministration in Patients With Mixed Hyperlipidemia | |||||||||||||
Medical condition: Mixed hyperlipidemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) AT (Completed) GB (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-002090-23 | Sponsor Protocol Number: K-111-2.02EU | Start Date*: 2005-02-03 |
Sponsor Name:Kowa Research Europe Ltd. | ||
Full Title: A phase IIa multicentre randomised double-blind, double-dummy study to evaluate the efficacy and safety of K-111 versus Fenofibrate in patients with hyperlipidaemia. | ||
Medical condition: Hyperlipidaemia | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: HU (Completed) CZ (Completed) | ||
Trial results: View results |
EudraCT Number: 2005-003626-26 | Sponsor Protocol Number: 01-05-TL-475-016 | Start Date*: 2006-06-14 | |||||||||||
Sponsor Name:Takeda Europe R&D Centre Ltd | |||||||||||||
Full Title: A double-blind, placebo-controlled, randomized study to evaluate the efficacy and safety of TAK-475 or placebo when co-administered with current lipid-lowering therapy in subjects with homozygous f... | |||||||||||||
Medical condition: Treatment of primary dyslipidemia | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-004003-23 | Sponsor Protocol Number: ISIS703802 | Start Date*: 2016-09-28 | |||||||||||||||||||||
Sponsor Name:Ionis Pharmaceuticals, Inc. | |||||||||||||||||||||||
Full Title: A Placebo-Controlled, Dose-Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of ISIS 703802, Targeting ANGPTL3, Administered S... | |||||||||||||||||||||||
Medical condition: Heterozygous familial hypercholesterolemia and Homozygous familial hypercholesterolemia | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: IT (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2015-001934-19 | Sponsor Protocol Number: LPS14354 | Start Date*: 2016-02-15 | |||||||||||
Sponsor Name:Sanofi-Aventis Groupe | |||||||||||||
Full Title: A Randomized, Open-Label, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab Versus Usual Care in Patients with Type 2 Diabetes and Mixed Dyslipidemia at High Cardiovascular Ris... | |||||||||||||
Medical condition: Dyslipidemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Completed) DE (Completed) GB (Completed) SE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-001446-25 | Sponsor Protocol Number: FHGT002 | Start Date*: 2017-09-20 |
Sponsor Name:University of Pennsylvania | ||
Full Title: AAV8-mediated Low Density Lipoprotein Receptor (LDLR) Gene Replacement in Subjects with Homozygous Familial Hypercholesterolemia (HoFH) | ||
Medical condition: Adults with homozygous familial hypercholesterolemia | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Completed) IT (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2021-002192-19 | Sponsor Protocol Number: ISIS678354-CS5 | Start Date*: 2022-07-22 | ||||||||||||||||
Sponsor Name:Ionis Pharmaceuticals, Inc. | ||||||||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of ISIS 678354 Administered Subcutaneously to Patients with Severe Hypertriglyceridemia | ||||||||||||||||||
Medical condition: Severe hypertryglyceridemia | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: SE (Ongoing) NO (Ongoing) ES (Ongoing) HU (Ongoing) NL (Ongoing) CZ (Ongoing) FI (Ongoing) BG (Ongoing) SK (Ongoing) PT (Ongoing) PL (Ongoing) DK (Ongoing) IT (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-024064-18 | Sponsor Protocol Number: OM-EPA-003 | Start Date*: 2011-03-22 | |||||||||||
Sponsor Name:Omthera Pharmaceutical Inc. | |||||||||||||
Full Title: Efficacy and Safety of Epanova® in Severe Hypertriglyceridemia | |||||||||||||
Medical condition: Severe hypertriglyceridemia defined as serum triglyceride (TG) values ≥500 and <2000 mg/dL (≥5.65 mmol/L and <22.60 mmol/L). | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-003713-23 | Sponsor Protocol Number: CER-001-CLIN-009 | Start Date*: 2015-11-11 | |||||||||||
Sponsor Name:CERENIS THERAPEUTICS SA | |||||||||||||
Full Title: PHASE III, MULTI-CENTER, RANDOMIZED, 48 WEEKS, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED STUDY TO EVALUATE EFFICACY AND SAFETY OF CER-001 ON VESSEL WALL AREA IN PATIENTS WITH GENETICALLY DEF... | |||||||||||||
Medical condition: GENETICALLY DEFINED FAMILIAL PRIMARY HYPOALPHALIPOPROTEINEMIA (FPHA mutation in ApoA1 and/or ABCA1 gene) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Prematurely Ended) BE (Prematurely Ended) FR (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-005924-16 | Sponsor Protocol Number: M13-377 | Start Date*: 2012-06-13 | |||||||||||
Sponsor Name:Abbott Laboratories Ireland Limited | |||||||||||||
Full Title: A 12-week, Double-blind, Randomized Study to Compare the Efficacy and Safety of Fixed Combinations of Fenofibrate /Simvastatin 145/20mg and Fenofibrate / Simvastatin 145/40mg Tablets vs. Matching M... | |||||||||||||
Medical condition: Dyslipidemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-004496-39 | Sponsor Protocol Number: RGX-501-102 | Start Date*: 2020-08-12 |
Sponsor Name:REGENXBIO Inc. | ||
Full Title: A Long-term Follow-up Study to Evaluate the Safety and Efficacy of RGX-501 | ||
Medical condition: Adults with homozygous familial hypercholesterolemia | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2014-002358-38 | Sponsor Protocol Number: RET-D-001 | Start Date*: 2015-04-28 | |||||||||||
Sponsor Name:Travere Therapeutics, Inc. | |||||||||||||
Full Title: PROTOCOL RET-D-001: EFFICACY AND SAFETY OF SPARSENTAN (RE-021), A DUAL ENDOTHELIN RECEPTOR AND ANGIOTENSIN RECEPTOR BLOCKER, IN PATIENTS WITH FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS): A RANDOMIZED... | |||||||||||||
Medical condition: FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) IT (Ongoing) BE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-002539-24 | Sponsor Protocol Number: MICA | Start Date*: 2012-05-03 | |||||||||||
Sponsor Name:Hospital of the University of Munich | |||||||||||||
Full Title: Effect of Mipomersen on LDL-Cholesterol Levels in Patients with Severe LDL-Hypercholesterolemia and Atherosclerosis Treated by Regular LDL-Apheresis | |||||||||||||
Medical condition: In this trial, the effect of mipomersen is tested on LDL-cholesterol levels in patients with severe LDL-hypercholesterolemia and atherosclerosis which are regularly treated by LDL-apheresis. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-002315-25 | Sponsor Protocol Number: TAK-475/EC303 | Start Date*: 2005-12-15 | |||||||||||
Sponsor Name:Takeda Europe R&D Centre Ltd | |||||||||||||
Full Title: A double-blind, double dummy, randomized, parallel group, multi-centre Phase III study to evaluate the efficacy and safety of TAK-475 100 mg and TAK-475 100 mg administered in combination with ezet... | |||||||||||||
Medical condition: Treatment of patients with primary dyslipidaemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) EE (Completed) FI (Completed) LV (Completed) LT (Completed) HU (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-002536-67 | Sponsor Protocol Number: ISIS678354-CS3 | Start Date*: 2021-04-15 | ||||||||||||||||
Sponsor Name:Ionis Pharmaceuticals, Inc. | ||||||||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of AKCEA‑APOCIII‑LRX Administered Subcutaneously to Patients with Familial Chylomicronemia Syndrome (FCS) | ||||||||||||||||||
Medical condition: Familial Chylomicronemia Syndrome (FCS) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) SE (Completed) NO (Completed) FR (Completed) PT (Completed) SK (Completed) HU (Completed) NL (Ongoing) ES (Ongoing) IT (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-000620-28 | Sponsor Protocol Number: LPS14245 | Start Date*: 2015-07-06 | |||||||||||
Sponsor Name:sanofi-aventis groupe | |||||||||||||
Full Title: A Multi-Country, Multicenter, Single-Arm, Open-Label Study to Document the Safety, Tolerability and Effect of Alirocumab on atherogenic lipoproteins in High Cardio-Vascular Risk Patients With Sever... | |||||||||||||
Medical condition: Hypercholesterolemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) CZ (Completed) SK (Completed) BE (Completed) IT (Completed) HU (Completed) AT (Completed) DE (Completed) FR (Completed) SE (Completed) ES (Completed) FI (Completed) PL (Completed) GR (Completed) SI (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-002810-11 | Sponsor Protocol Number: R727-CL-1609 | Start Date*: 2018-11-19 | |||||||||||||||||||||||||||||||
Sponsor Name:Regeneron Pharmaceuticals, Inc. | |||||||||||||||||||||||||||||||||
Full Title: Long Term Safety Study of PRALUENT in Patients with Heterozygous Familial Hypercholesterolemia or with Non-Familial Hypercholesterolemia at High and Very High Cardiovascular Risk and Previously Enr... | |||||||||||||||||||||||||||||||||
Medical condition: Heterozygous Familial Hypercholesterolemia or Non-Familial Hypercholesterolemia at High and Very High Cardiovascular Risk | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: EE (Prematurely Ended) BG (Completed) | |||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2021-003280-95 | Sponsor Protocol Number: ISIS678354-CS13 | Start Date*: 2022-06-16 | ||||||||||||||||
Sponsor Name:Ionis Pharmaceuticals, Inc. | ||||||||||||||||||
Full Title: An Open-Label Extension Study of AKCEA-APOCIII-LRX Administered Subcutaneously to Patients with Familial Chylomicronemia Syndrome (FCS) | ||||||||||||||||||
Medical condition: Familial Chylomicronemia Syndrome (FCS) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Ongoing) NL (Ongoing) NO (Completed) PT (Ongoing) SK (Ongoing) IT (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-002997-28 | Sponsor Protocol Number: ISIS304801-CS20 | Start Date*: 2021-03-17 | |||||||||||
Sponsor Name:Akcea Therapeutics, Inc. | |||||||||||||
Full Title: An Open-Label Study of Volanesorsen (ISIS 304801) Administered Subcutaneously to Pediatric Patients with Familial Chylomicronemia Syndrome (FCS) | |||||||||||||
Medical condition: Familial Chylomicronemia Syndrome | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-000641-13 | Sponsor Protocol Number: BIO89-100-221 | Start Date*: 2020-09-30 | |||||||||||
Sponsor Name:89bio, Inc. | |||||||||||||
Full Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Explore the Efficacy and Safety of BIO89-100 in Subjects with Severe Hypertriglyceridemia | |||||||||||||
Medical condition: Severe Hypertriglyceridemia (SHTG) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) CZ (Completed) PL (Completed) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.